Bouanchaud D H
Rhône-Poulenc Rorer, Centre de Recherche de Vitry-Alfortville, Vitry-sur Seine, France.
J Antimicrob Chemother. 1997 May;39 Suppl A:15-21. doi: 10.1093/jac/39.suppl_1.15.
Quinupristin/dalfopristin is a new water-soluble streptogramin antimicrobial agent comprising quinupristin and dalfopristin in a ratio of 30:70. The in-vitro spectrum of activity includes most multi-resistant Gram-positive aerobes, important Gram-negative aerobes, Gram-positive anaerobes and intracellular bacteria that are causal agents of respiratory, blood and cutaneous infections. Of particular note, quinupristin/dalfopristin is active against multidrug-resistant isolates of Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium, and against penicillin-resistant and/or erythromycin-resistant Streptococcus pneumoniae. The combination is also active against staphylococci showing both constitutive and inducible erythromycin resistance. Bactericidal activity and a prolonged post-antibiotic effect have also been noted for quinupristin/dalfopristin against Gram-positive cocci. Gram-negative bacteria susceptible to quinupristin/dalfopristin include Moraxella catarrhalis, Legionella spp. and Mycoplasma spp. Overall, the spectrum of antibacterial activity indicates a potential role for this combination in the treatment of difficult-to-treat Gram-positive infections, including those caused by multidrug-resistant organisms. Since this activity extends to Gram-negative respiratory bacteria, quinupristin/dalfopristin may also find a role in the treatment of atypical, as well as typical, pneumonia.
奎奴普丁/达福普汀是一种新型水溶性链阳菌素抗菌剂，由奎奴普丁和达福普汀按30:70的比例组成。其体外抗菌谱包括大多数多重耐药革兰氏阳性需氧菌、重要的革兰氏阴性需氧菌、革兰氏阳性厌氧菌以及引起呼吸道、血液和皮肤感染的细胞内细菌。特别值得注意的是，奎奴普丁/达福普汀对金黄色葡萄球菌、表皮葡萄球菌和粪肠球菌的多重耐药菌株，以及对青霉素耐药和/或红霉素耐药的肺炎链球菌具有活性。该组合对同时表现出组成型和诱导型红霉素耐药的葡萄球菌也有活性。奎奴普丁/达福普汀对革兰氏阳性球菌也具有杀菌活性和延长的抗生素后效应。对奎奴普丁/达福普汀敏感的革兰氏阴性菌包括卡他莫拉菌、军团菌属和支原体属。总体而言，抗菌活性谱表明该组合在治疗难治性革兰氏阳性感染（包括由多重耐药菌引起的感染）中具有潜在作用。由于这种活性扩展到革兰氏阴性呼吸道细菌，奎奴普丁/达福普汀在治疗非典型肺炎以及典型肺炎中可能也有作用。
